Product Showcase

These non-CME presentations can add to your educational conference experience. See company products and services that can help you in your practice, and receive a boxed meal. All events take place in Product Showcase I and Product Showcase II, located in the Exhibit Hall, during conference breaks and are limited to 150 participants. Make plans now to visit one (or more) of the daily presentations.

What will you get when you attend?

  • Get the latest information and research, while interacting with key experts on the newest products in emergency medicine
  • Did we mention FREE boxed meal
 

Product Showcase Schedule

Sunday, October 29th

Janssen Pharmaceuticals

 

Time:10:30 am - 11:15 am
Location: Product Showcase I
Speaker(s): James M. Williams, MS, DO, FACEP

Improving Clinical Practice in Patients With NVAF

This lecture will present options for reducing the risk of stroke in patients with nonvalvular atrial fibrilation (NVAF). This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

 

Shire Pharmaceuticals

 

Time: 10:30 am - 11:15 am
Location: Product Showcase II
Speaker(s): Huamin Henry Li, MD, PhD

Medical Mystery, A Case of Unexplained Asphyxia

Participants are invited to test their diagnostic skills and uncover the cause of our patient’s symptoms during the presentation at this Medical Mystery.

 

Edwards Lifesciences

 

Time: 2:30 pm - 3:15 pm
Location: Product Showcase I
Speaker(s): James F. Neuenschwander, II, MD and Kimberly Del Monte, RN

Is My Patient in Shock? Noninvasive Solutions to Assessing Shock States

Please join us for this interactive workshop that introduces the concepts of a noninvasive approach to assessing shock states in patients admitted to the emergency department. Acutely ill patients present with hemodynamic profiles which differ in patient cohorts with suspected Acute Heart Failure (AHF), sepsis and stroke. These initial HD measurements could play a role in improving diagnosis and developing individualized therapeutic management plans.1 The ClearSign system is a simple noninvasive technology that provides continuous real-time advanced hemodynamic information for critically ill patients. Continuous access to advanced hemodynamic parameters offers immediate insight into patient physiologic status, giving you the clarity to make more informed volume administration decisions. 1 Nowak, et al. Noninvasive Hemodynamic Monitoring in Emergency Patients with Suspected Heart Failure, Sepsis and Stroke: The PRemium Registry. Western J of Emerg Med 2014

 

Roche Diagnostics

 

Time: 2:30 pm - 3:15 pm
Location: Product Showcase II
Speaker(s): Glen Hansen, PhD, D(ABMM), FCCM

Influenza Testing in the ED: Past, Present and Future

Influenza is a significant cause of morbidity and mortality contributing to more than 200,000 hospitalizations and up to 50,000 deaths annually in the U.S. alone. Debate over diagnostic approaches for detecting influenza continues. Studies show that rapid antigen assays fail to detect as many as 50 percent of cases detected by reverse transcriptase polymerase chain reaction (RT-PCR) testing. Concerns over assays with poor sensitivity have led to algorithmic approaches advocated by the CDC to address the poor negative predictive value of rapid antigen testing. However, deference to clinical symptoms alone may miss as many as 50 to 60 percent of influenza cases. Novel molecular assays capable of detecting influenza within the ED visit are available. This presentation will focus on the challenges faced in diagnosing influenza during season in the ED and highlight one approach for supporting clinical management of suspected influenza cases using a novel rapid RT-PCR test.

 

Monday, October 30th

EKOS Corporation

 

Time: 11:30 am - 12:15 pm
Location: Product Showcase I
Speaker(s): Michael Sore, MD

A Standard-Changing Approach to the Management of Acute PE: An ER Perspective

Join us to learn how the treatment of PE is changing and the part you play in the ER. Learn the difference between traditional treatment and the effective low-dose lytic options for interventional treatment. Get new ideas on how to risk stratify your patients and get educated on the latest approach to PE patient care. Change the status quo and proactively transform the quality of care for PE patients.

 

Aerogen

 

Time: 11:30 am - 12:15 pm
Location: Product Showcase II
Speaker(s): Lynne McCullough, MD

Increasing Throughput in the Emergency Department With High Performance Vibrating Mesh Technology

The session will focus on the important factors to consider when dealing with respiratory patients in the emergency department, and the use of high performance vibrating mesh technology to address these needs. The presentation will review case studies on critical respiratory patients in the emergency department. The objectives of the showcase are to:

  • Evaluate the evidence of increased throughput in the emergency department as a result of high performance aerosol technology.
  • Discuss the benefits of delivering aerosol therapy without the need for supplemental O2.
  • Examine the impact of high-performance technology on de-escalation of care for patients with a history of high acuity respiratory presentations.
 

Fisher & Paykel

 

Time: 2:30 pm - 3:15 pm
Location: Product Showcase I
Speaker(s): John Fraser, MBChB, PhD, MRCP, FRCA, FFARCSI, FCICM

Optiflow™ Nasal High Flow in the ER and Across the Care Continuum

Oxygen (O2) is one of the principal therapies provided across the care continuum. Traditionally, O2 has been delivered using standard nasal prongs or masks. However, patients are unable to tolerate these unconditioned gases, therefore their masimal flow rates are limited to 15 L/min. At these flow rates, the patients’ inspiratory flow demand is not met and, as a result, room air is entrained diluting the supplemental O2 and significantly decreasing the fraction of delivered inspired oxygen (F1O2). In contrast, Nasal High Flow (NHF) therapy delivers totally conditioned gas via nasal cannula at a range of flows (up to 60 L/min). These flows of gas also provide a degree of dynamic positive pressure and a clearance of CO2 from within the anatomical dead space. The range of F1O2 that can be accurately delivered is between 21 and 100 percent. A reduction in work of breathing has been demonstrated. NHF has many proven clinical and physiological benefits which are achieved through a variety of mechanisms. The objectives for this showcase are to:

  • Overview the current evidence for NHF therapy, including its mechanisms of action
  • Evaluate the emerging and clinically significant applications for NHF in the ED
  • Discuss the use of NHF both in the ED and beyond.
 

CSL Behring

 

Time: 2:30 pm - 3:15 pm
Location: Product Showcase II
Speaker(s): David M. Janicke, MD, PhD

Urgent Warfarin Reversal for Fast and Sustained Action: A Case-Based Presentation

Please join us for a case-based educational session. Dr. David Janicke of the University at Buffalo will explore clinical situations in which rapid reversal of warfarin is required in patients who experience acute major bleeding, as well as patients on warfarin therapy in need of urgent surgery/invasive procedures. This program will review the clinical data for a single-dose, US Food & Drug Administration-approved alternative to plasma for urgent warfarin reversal. Please arrive early as space is limited.

 

Tuesday, October 31st

BMS/Pfizer

 

Time: 11:30 am - 12:15 pm
Location: Product Showcase I
Speaker(s): Robert Dunne, MD

Treatment of VTE and Reduction in the Risk of Recurrent VTE Following Initial Therapy

Preview of clinical trial information that led to FDA approval of Apixiban for the treatment of DVT and PE, and risk of recurrent DVT/PE following initial therapy. Both AMPLIFY and AMPLIFYExtend efficacy and safety data will be discussed, with time allocated throughout the presentation to ask questions.

 

Portola Pharmaceuticals, Inc.

 

Time: 11:30 am - 12:15 pm
Location: Product Showcase II
Speaker(s): Marc Cohen, MD, FACC

In-Hospital to Home: New Standards for Extended-Duration VTE Prophylaxis in Acutely Ill Medical Patients

Please join us for a Product Showcase sponsored by Portola Pharmaceuticals. The objectives of this program include the following:

  • Review the burden of VTE in acutely ill medical patients
  • Provide an overview of the unmet need for extended-duration VTE prophylaxis from in-hospital to home
  • Review the APEX clinical trial data.
 

ACELRX

 

Time: 2:30 pm - 3:15 pm
Location: Product Showcase I
Speaker(s): James Miner, MD and Pamela Palmer, MD, PhD

Frontline Therapy: A New Approach to ED Pain Management

Establishing IV access in a busy ED can be challenging, timeconsuming and resource intensive; especially when the patient has difficult IV access. When the patient is also suffering from moderateto- severe acute pain, this delay in analgesic administration can cause significant anxiety and needless suffering. Our faculty will discuss a new approach to pain management that alleviates the challenges with IV access and potentially addresses unmet needs regarding management of acute pain in the ED setting. Safety and efficacy data from clinical trials, including patients presenting to the ED with moderate-to-severe acute pain, will be reviewed.

 

Janssen Pharmaceuticals

 

Time: 2:30 pm - 3:15 pm
Location: Product Showcase II
Speaker(s): James Neuenschwander, MD

Clinical Data and Real-World Evidence to Support DVT/PE Treatment Decision Making

This lecture will discuss treatment options for patients with deep vein thrombosis (DVT) and pulmonary embolism (PE), and how they can reduce the risk of recurrent thrombotic events. This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

 
 

Book Your Hotel

Virtual ACEP